Caris Life Sciences, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | $812.0M | $412.3M | $306.1M | — |
| Research and development | $101.6M | $113.9M | $116.9M | — |
| Operating income | $45.1M | -$257.1M | -$319.6M | — |
| Interest expense | $56.9M | $50.0M | $31.6M | — |
| Pretax income | -$68.1M | -$281.9M | -$341.4M | — |
| Income tax expense | $0 | $0 | $0 | — |
| Net income | -$68.1M | -$281.9M | -$341.4M | — |
| Balance Sheet | ||||
| Cash and equivalents | $796.3M | $64.0M | — | — |
| Current assets | $997.8M | $215.7M | — | — |
| Total assets | $1.1B | $343.7M | — | — |
| Current liabilities | $127.1M | $165.4M | — | — |
| Total liabilities | $548.4M | $620.9M | — | — |
| Stockholders' equity | $577.3M | -$2.5B | -$2.1B | -$1.7B |
| Cash Flow Statement | ||||
| Cash from operations | $83.2M | -$245.2M | -$276.1M | — |
| Depreciation and amortization | $22.6M | $48.9M | $49.0M | — |
| Stock-based compensation | $70.0M | $18.6M | $15.2M | — |
| Capital expenditure | $16.3M | $8.4M | $22.3M | — |
| Free cash flow | $66.9M | -$253.6M | -$298.4M | — |
| Share repurchases | $113,000 | $0 | $0 | — |
| Impairments | $0 | $0 | $0 | — |
Shares outstanding 282.7M
Annual filing data through FY ended December 31, 2025; float as of July 2, 2026.